Evidence map›Paper›PMID 27503578›Full record

ArticleThe pharmacogenomics journal2017

Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms.

K Kubo, M Ohara, M Tachikawa, L H Cavallari, M T M Lee, M S Wen, M G Scordo, E A Nutescu, M A Perera, A Miyajima and 5 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Warfarin: The End or the End of One Size Fits All Therapy?Journal of personalized medicine · 2018
    Review
  10. Evaluation ofFuture science OA · 2018
    Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 5 countries.

K KuboDepartment of Biopharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
M OharaDepartment of Biopharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
M TachikawaDepartment of Biopharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
L H CavallariDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, FL, USA.
M T M LeeGenomic Medicine Institute, Geisinger Health System, Danville, PA, USA.
M S WenDepartment of Internal Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
M G ScordoDepartment of Medical Sciences, Clinical Pharmacology, Uppsala University Hospital, Uppsala, Sweden.
E A NutescuDepartment of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA.
M A PereraDepartment of Medicine, Section of Genetic Medicine, University of Chicago, Chicago, IL, USA.
A MiyajimaDepartment of Biopharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
N KanekoDepartment of Biopharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
V PengoDepartment of Cardiothoracic and Vascular Sciences, University of Padova, Padova, Italy.
R PadriniDepartment of Medicine DIMED, University of Padova, Padova, Italy.
Y T ChenDivision of Epidemiology and Genetics, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
H TakahashiDepartment of Biopharmaceutics, Meiji Pharmaceutical University, Tokyo, Japan.
Meiji Pharmaceutical University · JPUniversity of Padua · ITChang Gung University · TWGeisinger Health System · USInstitute of Biomedical Sciences, Academia Sinica · TWUniversity of Chicago · USUniversity of Florida · USUniversity of Illinois Chicago · USUppsala University Hospital · SE

Funding

Comprehensive studies of novel SNPs affecting warfarin dose in African AmericansR21HL106097 · NHLBI · UNIVERSITY OF CHICAGO · PI PERERA, MINOLI A · 2011 to 2012
$437k
NHLBI NIH HHS R21 HL106097
6 · The paper itself

Abstract

Using population pharmacokinetic analysis (PPK), we attempted to identify predictors of S-warfarin clearance (CL(S)) and to clarify population differences in S-warfarin pharmacokinetics among a cohort of 378 African American, Asian and white patients. Significant predictors of CL(S) included clinical (age, body weight and sex) and genotypic (CYP2C9*2,*3 and *8) factors, as well as African American ethnicity, the median CL(S) being 30% lower in the latter than in Asians and whites (170 versus 243 and 250 ml h

Indexed as

AnticoagulantsWarfarinAlgorithmsAsian PeopleBlack or African AmericanCohort StudiesCytochrome P-450 CYP2C9Dose-Response Relationship, DrugFemaleGenotypeHumansMaleMetabolic Clearance RateMiddle AgedModels, BiologicalPharmacogenomic TestingAnticoagulantsCYP2C9 protein, humanCytochrome P-450 CYP2C9Vitamin K Epoxide ReductasesVKORC1 protein, humanWarfarin

Identifiers

PMID27503578
OpenAlexW2515683381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.